Schüpke S, Neumann FJ, Menichelli M, et al. - In this multicenter, randomized, open-label trial, researchers randomized 4,018 individuals, to receive either ticagrelor or prasugrel, who presented with acute coronary syndromes and for whom invasive assessment was planned in order to assess related benefits of ticagrelor in comparison with prasugrel in individuals with acute coronary syndromes. Among individuals who presented with acute coronary syndromes with or without ST-segment elevation, among those who received prasugrel vs those who received ticagrelor, the incidence of death, myocardial infarction, or stroke was notably lower, and among the two groups, the incidence of major bleeding was not significantly distinctive.